Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Yakir Rottenberg; Albert Grinshpun; Iddo Z Ben-Dov; Esther Oiknine Djian; Dana G Wolf; Luna Kadouri

doi:10.1001/jamaoncol.2021.6764

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

JAMA Oncol. 2022 Feb 1;8(2):300-301. doi: 10.1001/jamaoncol.2021.6764.

Authors

Yakir Rottenberg^{1

2}, Albert Grinshpun³, Iddo Z Ben-Dov^{4

2}, Esther Oiknine Djian^{5

2}, Dana G Wolf^{5

2}, Luna Kadouri^{1

2}

Affiliations

¹ Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel.
² Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
³ Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Department of Nephrology and Hypertension, Hadassah Medical Center, Jerusalem, Israel.
⁵ Clinical Virology Unit, Department of Microbiology and Infectious Disease, Hadassah Medical Center, Jerusalem, Israel.

Abstract

This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.

MeSH terms

BNT162 Vaccine
COVID-19*
Humans
Neoplasms* / drug therapy
SARS-CoV-2
Vaccines, Synthetic
mRNA Vaccines

Substances

Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine